PRP for Tendon Injuries: A Tendon-by-Tendon Map of Where the Evidence Is Strong and Where It Collapses

The original element in this article is a tendon-by-tendon evidence map: a single comparison, assembled here from the published systematic reviews, of where randomized trial support for PRP in tendon injury is genuinely strong, where it is mixed, and where the best-quality studies are frankly negative. No individual review publishes this side by side, because reviews are organized by one tendon at a time. The clinical menu you are shown is organized the opposite way, as a single line item called "PRP for tendon pain," and that framing is the source of most disappointed patients.

Why tendons are not interchangeable. It is tempting to assume a tendon is a tendon. They are not, in the ways that matter for this treatment. They differ in blood supply, in mechanical load, in whether the painful tissue is the tendon body or its insertion, and in how much of the problem is degeneration versus inflammation. The word tendinitis is largely a misnomer in chronic cases: what is usually present is tendinosis, a degenerative failure of collagen repair with disorganized fibers and abnormal new blood vessels, and relatively little classic inflammation. That distinction is the entire theory behind PRP here. The concentrated platelets release growth factors intended to restart a repair process that has stalled, which is a rationale that makes sense for degeneration and makes much less sense for a mechanical tear.

Lateral epicondylitis, tennis elbow: the strongest case. This is where the evidence is most favorable and where the recommendation is easiest to defend. A 2024 systematic review and meta-analysis of randomized controlled trials in the American Journal of Sports Medicine found PRP produced better long-term functional improvement and pain relief for lateral epicondylitis than comparators (AJSM). The word doing the work in that sentence is long-term. The characteristic pattern across tennis elbow trials is that corticosteroid injection wins early, often at four to six weeks, and then loses, with PRP overtaking it somewhere in the three to six month range and holding the advantage after that. If you are choosing between the two, you are choosing between fast relief that fades and slow relief that lasts. That is a real, defensible choice, and it is also why comparing the two at six weeks, which is what many patients do informally, produces exactly the wrong conclusion.

Rotator cuff tendinopathy: favorable but narrower than the marketing. Here the picture is genuinely positive with an important qualifier. A double-blind randomized controlled trial in patients with partial-thickness tears or tendinopathy found PRP produced significantly better short-term pain relief and function than corticosteroid injection (Arthroscopy), and a systematic review and meta-analysis reached broadly supportive conclusions for rotator cuff tendinopathy (PLoS One). The qualifier is the population. These are studies of tendinopathy and partial-thickness change, not full-thickness tears. A full-thickness rotator cuff tear is a structural problem, and no injection is going to reattach a tendon that has detached. When a clinic offers PRP for "shoulder pain" without an imaging-based diagnosis, that is the distinction being glossed over.

Achilles tendinopathy: where the good evidence turns against it. This is the section most PRP marketing omits entirely, and it is the reason this article is organized as a map. Mid-portion Achilles tendinopathy has been studied with some of the better-designed placebo-controlled trials in the field, and those trials have generally failed to show benefit over saline injection when combined with an eccentric loading program. That is not a gap in the evidence, it is a finding, and it points the other way. It is also mechanistically instructive: the Achilles has poor blood supply in its mid-portion watershed zone, which is one of the leading explanations for why an injected biologic underperforms there. If someone offers you PRP for a mid-portion Achilles problem, the honest framing is that you would be trying something the better trials have not supported, which is a legitimate decision to make with your eyes open and an illegitimate one to make because a brochure implied otherwise.

Plantar fascia: mixed, and covered in more depth in our dedicated piece. Worth noting here only because the plantar fascia is not a tendon at all, it is an aponeurosis, and it is routinely marketed alongside tendon indications as if the biology transferred.

Patellar tendinopathy and gluteal tendinopathy: thin, and honestly so. Both have trials, neither has the volume or the consistency of the tennis elbow literature. Broad narrative reviews of PRP repeatedly return to the same structural complaint: heterogeneity of preparation and protocol makes pooling difficult (EFORT Open Reviews). Treat these as reasonable-to-try rather than evidence-supported.

The variable that undermines every comparison above. Here is the finding that should change how you read all of this, and it is the strongest argument for humility. "PRP" is not a standardized product. Preparations differ in platelet concentration, in whether white blood cells are included (leukocyte-rich versus leukocyte-poor), in whether the platelets are activated, in injection volume, in number of sessions, and in whether ultrasound guidance is used. Those are not trivial variations, and there is reasonable evidence that at least some of them matter clinically. A systematic review and meta-analysis specifically examining ultrasound-guided PRP for tendinopathies found guidance relevant to outcomes (Blood Transfusion), and a fundamentals review has catalogued the extent of preparation variability across the field (Arthroscopy). The consequence is uncomfortable: two studies both labelled "PRP for tendon X" may have injected substantially different products. When a review concludes the evidence is mixed, part of that mixture is the treatment itself not being one treatment.

What the studies do not tell you. Four specific gaps, named plainly. First, there is no established optimal platelet concentration for any tendon, which means the number your clinic's system produces is a manufacturing specification, not a therapeutic target. Second, there is very little head-to-head evidence on leukocyte-rich versus leukocyte-poor preparations by indication, despite strong theoretical arguments on both sides. Third, the optimal number of injections is unsettled; single versus series protocols coexist without a clear winner. Fourth, and most consequential for anyone deciding today, nearly every positive trial delivered PRP alongside a structured rehabilitation program, which means no study has cleanly isolated the injection from the loading protocol. It is entirely possible that part of what works is the exercise, and that the injection buys enough symptom relief to make the exercise tolerable. That would still be a useful treatment. It is a different claim from the one usually made.

How to use the map in a consultation. Three questions, and they are answerable. Ask which specific tendon and which specific pathology the diagnosis is, based on examination and imaging, not on the region that hurts. Ask what the evidence is for that exact indication rather than for PRP in general. And ask what the rehabilitation program alongside the injection will be, because if the answer is that there is not one, the treatment is being delivered differently from every trial that found it worked.

The honest summary is that PRP for tendon injury is neither the regenerative breakthrough of the marketing nor the placebo of the skeptics. It is a treatment with real randomized support at the lateral elbow, reasonable support in rotator cuff tendinopathy short of a full-thickness tear, weak or negative support at the mid-portion Achilles, and thin evidence elsewhere. Knowing which tendon you have is the entire decision, and it is worth understanding how PRP is prepared and how it compares to a cortisone shot before you agree to a package of sessions.